Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists investigate blood vessel cells to unlock secrets of bleeding disorder

NCT ID NCT07358013

Knowledge-focused Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study aims to understand how endothelial colony-forming cells (ECFCs) behave in people with von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS) compared to healthy individuals. Researchers will collect blood samples from 48 participants to isolate ECFCs and measure how they produce and release von Willebrand factor. The goal is to learn more about the underlying biology of these bleeding disorders.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could improve understanding of how blood vessel cells contribute to von Willebrand disease, potentially pointing toward new ways to diagnose or manage the condition.
What could go wrong
This is a small, early-stage observational study with only 48 participants. It is not testing a treatment, so it will not directly lead to a cure or therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include the enrollment of subjects with a previous diagnosis of VWD or AVWS and a group of healthy volunteers (controls). Patients will be selected among those referred at Angelo Bianchi Bonomi Haemophilia and Thrombosis Center, with a previous diagnosis of VWD or AVWS. Healthy volunteers, defined as individuals without a previous diagnosis of bleeding or thrombotic disorders will be enrolled in equal number to cases with the aim of creating a ECFCs reference group. At enrollment, controls will undergo an interview to confirm their health status, they will be asked to sign the informed consent and then they will undergo a blood withdrawal necessary to confirm plasma VWF levels and to isolate ECFCs as already described for patients.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for patients: Patients with von Willebrand disease (VWD) or acquired von Willebrand syndrome (AVWS) Age ≥ 16 years. Previous diagnosis of von Willebrand disease or acquired von Willebrand syndrome, defined as one of the following: Group A - Type 1 VWD: VWF levels ≤ 30 IU/dL, regardless of bleeding history, or VWF levels ≤ 0.50 IU/mL in the presence of abnormal bleeding. Group B - Congenital or acquired VWD (VWD or AVWS): Diagnosis of congenital or acquired VWD, with or without gastrointestinal bleeding. Group C - Subgroup study (Type 2A VWD): One patient with type 2A VWD selected for a dedicated sub-study involving allele-specific siRNA silencing of the mutant allele. Ability and willingness to provide written informed consent. For patients without prior molecular characterization: willingness to undergo VWF gene sequencing and to sign the related informed consent. Inclusion criteria for healthy volunteers * No prior diagnosis of VWD, bleeding disorders, or thrombotic disorders. * Willingness to donate blood for study procedures. * Ability and willingness to provide written informed consent. * Age ≥ 18 years. Exclusion criteria for both patients and healthy volunteers: * Pregnancy. * Anemia, as determined at screening or based on medical history.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired von Willebrand disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired von willebrand syndrome von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acquired von Willebrand disease Von Willebrand disease (VWD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, A.B.Bonomi Hemophilia and Thrombosis Center

    RECRUITING

    Milan, 20122, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.